Cellectis (NASDAQ:CLLS) Announces Quarterly Earnings Results

Cellectis (NASDAQ:CLLS) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.41), FiscalAI reports. The company had revenue of $3.76 million for the quarter, compared to the consensus estimate of $15.61 million. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.

Cellectis Stock Down 11.3%

CLLS stock traded down $0.15 during midday trading on Friday, reaching $1.18. The company had a trading volume of 72,011 shares, compared to its average volume of 59,474. Cellectis has a 1 year low of $0.88 and a 1 year high of $5.45. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61. The company has a market capitalization of $118.40 million, a P/E ratio of -1.82 and a beta of 3.21. The company has a 50 day moving average of $1.49 and a two-hundred day moving average of $2.94.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CLLS. Robert W. Baird cut their target price on Cellectis from $10.00 to $8.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 15th. Citizens Jmp cut Cellectis from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 15th. Weiss Ratings upgraded Cellectis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. Barclays downgraded Cellectis from an “overweight” rating to an “underweight” rating and cut their price objective for the stock from $9.00 to $1.30 in a report on Wednesday, September 16th. Finally, Wells Fargo & Company reduced their price objective on shares of Cellectis from $4.00 to $3.00 and set an “equal weight” rating for the company in a research note on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $5.46.

About Cellectis

Cellectis is a biotechnology company focused on developing gene-edited cell and gene therapies, with an emphasis on treatments for cancer. Founded in France in 1999, the company operates in France and the United States. Its research centers on TALEN gene-editing technology, which it uses to modify cells for potential therapeutic applications. Cellectis is developing allogeneic CAR T-cell therapies made from donor T cells, an approach intended to create treatments that can be prepared for use by multiple patients rather than made individually for each patient.